Farmacie pro praxi. 2023;19(2):14-16

Rychle působící antidepresiva -otázky a odpovědi

prof. MUDr. Bc. Libor Ustohal, Ph.D., MUDr. Eliška Bartečková, Ph.D.
Psychiatrická klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice Brno

Published: June 7, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ustohal L, Bartečková E. Rychle působící antidepresiva -otázky a odpovědi. Pharmacy for Practice. 2023;19(2):14-16.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Witkin JM, Martin AE, Golani LK, Xu NZ, Smith JL. Rapid­‑acting antidepressants. In: Advances in Pharmacology [Internet]. Elsevier; 2019 [cited 2022 Dec 30]. p. 47-96. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1054358919300158 Go to original source...
    2. McIntyre RS. Rapid­‑acting antidepressants in psychiatry: psychedelics, episodic treatments, innovation, and clarion call for methodologic rigor in drug development. Expert Opin Drug Saf. 2022;21(6):715-6. Go to original source... Go to PubMed...
    3. K V A, Mohan AS, Chakravarty S. Rapid acting antidepressants in the mTOR pathway: Current evidence. Brain Res Bull. 2020;163:170-7. Go to original source... Go to PubMed...
    4. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and Psychedelic­‑Assisted Psychotherapy. Am J Psychiatry. 2020;177(5):391-410. Go to original source... Go to PubMed...
    5. Gass N, Becker R, Reinwald J, Cosa­‑Linan A, Sack M, Weber­‑Fahr W, et al. Differences between ketamine's short­‑term and long­‑term effects on brain circuitry in depression. Transl Psychiatry. 2019;9(1):172. Go to original source... Go to PubMed...
    6. Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin­‑assisted treatment for major depressive disorder: Prospective 12-month follow­‑up. J Psychopharmacol (Oxf). 2022;36(2):151-8. Go to original source... Go to PubMed...
    7. Savitz A, Wajs E, Zhang Y, Xu H, Etropolski M, Thase ME, et al. Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2 b, Randomized, Placebo­‑Controlled, Adaptive Dose­‑Finding Study. Int J Neuropsychopharmacol. 2021;24(12):965-76. Go to original source... Go to PubMed...
    8. Evropská agentura pro léčivé přípravky. SPRAVATO: Souhrn údajů o přípravku [Internet]. [cited 2022 Dec 30]. Available from: https://www.ema.europa.eu/en/documents/product­‑information/spravato­‑epar­‑product­‑information_cs.pdf.
    9. Ross S, Bossis A, Guss J, Agin­‑Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life­‑threatening cancer: a randomized controlled trial. J Psychopharmacol (Oxf). 2016;30(12):1165-80. Go to original source... Go to PubMed...
    10. Rossi GN, Hallak JEC, Bouso Saiz JC, Dos Santos RG. Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert Opin Drug Saf. 2022;21(6):761-76. Go to original source... Go to PubMed...
    11. Doyle MA, Ling S, Lui LMW, Fragnelli P, Teopiz KM, Ho R, et al. Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment. Expert Opin Drug Saf. 2022;21(6):733-43. Go to original source... Go to PubMed...
    12. Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord. 2019;258:11-24. Go to original source... Go to PubMed...
    13. Ionescu DF, Bentley KH, Eikermann M, Taylor N, Akeju O, Swee MB, et al. Repeat­‑dose ketamine augmentation for treatment­‑resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial. J Affect Disord. 2019;243:516-24. Go to original source... Go to PubMed...
    14. Chaudhury S, Kumar S, Soren S. Hallucinations: Etiology and clinical implications. Ind Psychiatry J. 2009;18(2):119. Go to original source... Go to PubMed...
    15. Bahji A, Zarate CA, Vazquez GH. Ketamine for Bipolar Depression: A Systematic Review. Int J Neuropsychopharmacol. 2021;24(7):535-41. Go to original source... Go to PubMed...
    16. Carhart­‑Harris RL, Goodwin GM. The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. 2017;42(11):2105-13. Go to original source... Go to PubMed...
    17. Callaway JC, Grob CS. Ayahuasca Preparations and Serotonin Reuptake Inhibitors: A Potential Combination for Severe Adverse Interactions. J Psychoactive Drugs. 1998 Dec;30(4):367-9. Go to original source... Go to PubMed...
    18. Andrashko V, Novak T, Brunovsky M, Klirova M, Sos P, Horacek J. The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication. Front Psychiatry. 2020 Aug 28;11:844. Go to original source... Go to PubMed...
    19. McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment­‑Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. Am J Psychiatry. 2021 May 1;178(5):383-99. Go to original source... Go to PubMed...
    20. Státní ústav pro kontrolu léčiv. CALYPSOL: Souhrn údajů o přípravku. Státní ústav pro kontrolu léčiv; 2021.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.